<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01759160</url>
  </required_header>
  <id_info>
    <org_study_id>NSFCfengxiar1</org_study_id>
    <secondary_id>Fengxia1</secondary_id>
    <nct_id>NCT01759160</nct_id>
  </id_info>
  <brief_title>Hemodynamic Responses During Induction: Comparison of Marsh and Schnider Pharmacokinetic Models</brief_title>
  <acronym>TCI</acronym>
  <official_title>Hemodynamic Responses During Induction: Comparison of Marsh and Schnider Pharmacokinetic Models in Propofol Plasma Target-controlled Infusion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>First Affiliated Hospital, Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>First Affiliated Hospital, Sun Yat-Sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the hemodynamic changes during anesthesia induction between Marsh and Schnider
      plasma TCI models. We put forward a hypothesis that, if one TCI model is associated with much
      more prominent vasodilation effect or cardiac depression, a more sharp decrease in mean
      arterial pressure, systemic vascular resistance , central venous return or stroke volume
      would be observed.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Current systems of propofol TCI are pre-programmed with the Marsh and Schnider
      pharmacokinetic models. Rate constants of Marsh are fixed, whereas compartment volumes and
      clearances are weight proportional. Schnider model has fixed values for VC, V3, k13, and k31,
      adjusts V2, k12, and k21 for age, and adjusts k10 according to total weight, lean body mass
      (LBM), and height. One major beneﬁt of the Schnider model is that it adjusts doses and
      infusion rates according to patient age. This provides a strong argument for using the
      Schnider model in the elderly and unwell patients which may improve hemodynamic stability and
      safety.

      However for the vast majority of young and middle age patients, whether Marsh or Schnider
      would be a better choice for hemodynamic stability remains unknown.

      With marsh model, as VC is scaled to body weight, the amount of drug delivered is dependent
      of body weight. In the Schnider model, as VC at 4.27L is independent of body weight, VC in
      terms of ml/kg decreases as body weight increases. This and the influence of height and
      weight on clearance results in heavier patients receiving less propofol on a mg/kg basis
      whereas those with a lower lean body mass will initially receive about 30% less than
      delivered by Marsh, but after 30 min, the Schnider model delivers about 15% more. Besides,
      when Schnider model is used in the morbidly obese, the LBM equation can generate paradoxical
      values resulting in excessive increases in maintenance infusion rates. Nevertheless, the
      purpose of this study was to investigate the vast majority of Asian patients whose body
      weight were in normal range. Only patients with BMI between 18 and 29 were included to
      minimize the influential factor of body weight in TCI system.

      To compare the hemodynamic changes during anesthesia induction between Marsh and Schnider
      plasma TCI models. We put forward a hypothesis that, if one TCI model is associated with much
      more prominent vasodilation effect or cardiac depression, a more sharp decrease in mean
      arterial pressure, systemic vascular resistance , central venous return or stroke volume
      would be observed.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>SVI (Stroke Volume Index) Value Change From Baseline Level at the End of the First 25 Minutes.</measure>
    <time_frame>The end of the first 25 minutes after propofol infusion</time_frame>
    <description>After propofol infusion started, according to sedation level, TCI targets were gradually titrated to reach a state of equilibrium at the end of the first 25 minutes. SVI were continuously monitored, at the end of the first 25 minutes, value change from baseline level were calculated.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>NI (Narcotrend Index) Reduction</measure>
    <time_frame>25 minutes after propofol infusion</time_frame>
    <description>Narcotrend was utilized to continuously record patients' sedation level during induction, provided as a criteria for Cpt (Plasma Target Concentration) adjustment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CVP (Central Venous Pressure)</measure>
    <time_frame>25 minutes after induction</time_frame>
    <description>CVP was continuously monitored to assess preload condition and served to calculate SVRI (systemic vascular resistance index) every minute during the first 25 minutes of infusion.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Marsh</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Marsh Plasma TCI with high initial target</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Schnider</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Schnider Plasma TCI with high initial target</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Marsh Plasma TCI with high initial target</intervention_name>
    <description>plasma target-controlled infusion in Marsh model(n=30) with an initial target concentration of 4 μg/ml. Target was then reset and gradually titrated to a sedation level with narcotrend index below 64.</description>
    <arm_group_label>Marsh</arm_group_label>
    <other_name>Plasma target-controlled infusion in Marsh model</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Schnider Plasma TCI with high initial target</intervention_name>
    <description>plasma target-controlled infusion in Schnider model(n=30) with an initial target concentration of 4 μg/ml. Target was then reset and gradually titrated to a sedation level with narcotrend index below 64.</description>
    <arm_group_label>Schnider</arm_group_label>
    <other_name>Plasma target-controlled infusion in Schnider model</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients between the ages of 18 years and 70 years

          -  ASA physical status I and II

          -  surgical procedures requiring general anesthesia with continuous CVP and arterial
             pressure monitoring.

        Exclusion Criteria:

          -  Patients younger than 16 y or older than 65 y

          -  Body Mass Index (BMI) &lt;18 or &gt;30

          -  emergency surgery

          -  allergy to any of the drugs used

          -  inability to communicate effectively

          -  severe cardiovascular dysfunction

          -  patient refusal and patients on long-term opioids or sedative medication.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xia Feng, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliaed Hospital of Sun Yat-sen University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 20, 2012</study_first_submitted>
  <study_first_submitted_qc>January 1, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 3, 2013</study_first_posted>
  <results_first_submitted>January 16, 2013</results_first_submitted>
  <results_first_submitted_qc>February 16, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 22, 2013</results_first_posted>
  <last_update_submitted>March 21, 2013</last_update_submitted>
  <last_update_submitted_qc>March 21, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 29, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>First Affiliated Hospital, Sun Yat-Sen University</investigator_affiliation>
    <investigator_full_name>Xia Feng</investigator_full_name>
    <investigator_title>Department of Anesthesiology</investigator_title>
  </responsible_party>
  <keyword>Target control infusion</keyword>
  <keyword>propofol</keyword>
  <keyword>cardiac depression</keyword>
  <keyword>induction of anesthesia</keyword>
  <keyword>hemodynamics</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propofol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The recruitment process started from Dec. 2012, ended in Jan.2013. Study location is The First Affiliated Hospital of Sun Yat-sen University.</recruitment_details>
      <pre_assignment_details>enrolled participants were excluded when they were found allergic to drugs used during the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Marsh</title>
          <description>Plasma TCI in Marsh Model with an initial target of 4 μg/ml, gradually titrated according to sedation level.</description>
        </group>
        <group group_id="P2">
          <title>Schnider</title>
          <description>Plasma TCI in Schnider Model with an initial target of 4 μg/ml, gradually titrated according to sedation level.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Marsh</title>
          <description>Plasma TCI in Marsh Model with an initial target of 4 μg/ml, gradually titrated according to sedation level.</description>
        </group>
        <group group_id="B2">
          <title>Schnider</title>
          <description>Plasma TCI in Schnider Model with an initial target of 4 μg/ml, gradually titrated according to sedation level.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
            <count group_id="B2" value="30"/>
            <count group_id="B3" value="60"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40.1" spread="13.1"/>
                    <measurement group_id="B2" value="41.6" spread="10.6"/>
                    <measurement group_id="B3" value="40.9" spread="11.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>China</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>SVI (Stroke Volume Index) Value Change From Baseline Level at the End of the First 25 Minutes.</title>
        <description>After propofol infusion started, according to sedation level, TCI targets were gradually titrated to reach a state of equilibrium at the end of the first 25 minutes. SVI were continuously monitored, at the end of the first 25 minutes, value change from baseline level were calculated.</description>
        <time_frame>The end of the first 25 minutes after propofol infusion</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Marsh</title>
            <description>Plasma TCI in Marsh Model with an initial target of 4 μg/ml, gradually titrated according to sedation level.</description>
          </group>
          <group group_id="O2">
            <title>Schnider</title>
            <description>Plasma TCI in Schnider Model with an initial target of 4 μg/ml, gradually titrated according to sedation level.</description>
          </group>
        </group_list>
        <measure>
          <title>SVI (Stroke Volume Index) Value Change From Baseline Level at the End of the First 25 Minutes.</title>
          <description>After propofol infusion started, according to sedation level, TCI targets were gradually titrated to reach a state of equilibrium at the end of the first 25 minutes. SVI were continuously monitored, at the end of the first 25 minutes, value change from baseline level were calculated.</description>
          <units>ml/beat/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-31.1" spread="9.8"/>
                    <measurement group_id="O2" value="-31.7" spread="9.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>NI (Narcotrend Index) Reduction</title>
        <description>Narcotrend was utilized to continuously record patients' sedation level during induction, provided as a criteria for Cpt (Plasma Target Concentration) adjustment.</description>
        <time_frame>25 minutes after propofol infusion</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CVP (Central Venous Pressure)</title>
        <description>CVP was continuously monitored to assess preload condition and served to calculate SVRI (systemic vascular resistance index) every minute during the first 25 minutes of infusion.</description>
        <time_frame>25 minutes after induction</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Marsh</title>
          <description>Plasma TCI in Marsh Model with an initial target of 4 μg/ml, gradually titrated according to sedation level.</description>
        </group>
        <group group_id="E2">
          <title>Schnider</title>
          <description>Plasma TCI in Schnider Model with an initial target of 4 μg/ml, gradually titrated according to sedation level.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac Arrhythmia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension (Systolic blood pressure lower than 75mmHg)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Xia Feng</name_or_title>
      <organization>First Affiliated Hospital of Sun Yat-sen University</organization>
      <phone>008613688877856</phone>
      <email>fengxiar@yahoo.cn</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

